Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2023-01-16 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
上海信公轶禾企业管理咨询有限公司关于益方生物科技（上海）股份有限公司2022年限制性股票激励计划首次授予相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the 2022 restricted stock incentive plan of a company. It contains detailed information about the stock incentive plan, including approval procedures, grant conditions, and advisor opinions. It is not a general annual or quarterly financial report, nor is it a simple announcement or certification. The content focuses on the stock incentive plan and the independent financial advisor's review and opinion on it. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone advisory report related to a specific financial incentive plan and compliance with regulations, rather than a full annual report or other categories. FY 2022
2023-01-16 Chinese
益方生物独立董事关于第一届董事会2023年第一次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of a company regarding resolutions passed at the first board meeting of 2023. It discusses adjustments to a 2022 restricted stock incentive plan, approval of the initial grant of restricted stock, and approval of senior management's 2022 bonuses and 2023 salary plans. The content focuses on governance and management decisions related to compensation and stock incentives, rather than financial results, audit opinions, or regulatory filings. It is not a full annual or interim report, nor an earnings release or capital update. The document is a formal board/management related announcement concerning executive compensation and stock incentive plans, fitting the category of Board/Management Information (MANG). The document length is short (2090 characters) and contains substantive content, so it is not a mere announcement of a report (RPA) or a regulatory filing (RNS).
2023-01-16 Chinese
益方生物第一届董事会2023年第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the first board meeting of 2023 for Yifang Bio-Technology (Shanghai) Co., Ltd. It details the meeting date, attendance, voting results, and specific agenda items such as adjustments to the 2022 restricted stock incentive plan, granting of restricted stock, and approval of senior management compensation plans. The content focuses on board decisions and management matters rather than financial results or regulatory filings. There is no indication of it being an annual report, earnings release, or other financial report. The document is not a proxy solicitation or voting results announcement but rather a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and contains detailed board meeting decisions, not just an announcement of a report publication or certification, so it is not RPA or RNS. Confidence is high due to clear keywords like "董事会会议决议公告" (board meeting resolution announcement), voting results, and management compensation discussion.
2023-01-16 Chinese
益方生物第一届监事会2023年第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the first meeting of the Supervisory Board of Yifang Bio-Technology (Shanghai) Co., Ltd. in 2023. It details the approval of adjustments to the 2022 restricted stock incentive plan and the initial grant of restricted stock to incentive recipients. The document includes voting results and references to related announcements published on the Shanghai Stock Exchange website. The content focuses on corporate governance decisions related to stock incentive plans rather than financial results, audit opinions, or management reports. It is not a full annual or interim report, earnings release, or audit report. It is also not a proxy solicitation or voting results declaration. The document is a formal board/management information announcement about supervisory board meeting resolutions and stock incentive plan approvals. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2391 characters, which is consistent with a meeting resolution announcement rather than a full report.
2023-01-16 Chinese
益方生物关于调整2022年限制性股票激励计划相关事项的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding adjustments to the 2022 restricted stock incentive plan of the company. It details board and shareholder meeting approvals, adjustments to the list of incentive recipients, legal and independent director opinions, and confirms compliance with relevant laws and regulations. The content focuses on changes to a stock incentive plan and related governance matters rather than financial results, earnings, or audit reports. It is not a full annual or interim report, nor a call transcript or earnings release. It is a regulatory announcement about management and board decisions related to equity incentives. This fits best under Regulatory Filings (RNS), as it is a formal regulatory announcement that does not fit other specific categories like Remuneration Information or Board/Management Information exactly, but relates to governance and regulatory compliance disclosures.
2023-01-16 Chinese
益方生物科技（上海）股份有限公司2022年限制性股票激励计划首次授予激励对象名单（截至授予日）
Share Issue/Capital Change Classification · 95% confidence The document is titled as a list of recipients for a 2022 restricted stock incentive plan, detailing the allocation of restricted shares to employees and reserved shares. It includes specific numbers of shares granted and percentages relative to total company stock. This is a disclosure related to share-based compensation, specifically the initial grant under a stock incentive plan. It is not a full annual or interim report, nor an earnings release or management discussion. It is not a regulatory filing or announcement of a report publication. The content fits best under the category of Share Issue/Capital Change (SHA), as it relates to the issuance of restricted stock under an incentive plan.
2023-01-16 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.